作者: Junjie Shen , Wenxu Zhao , Cheng Qian , Yanan Qi , Jiabing Ma
DOI: 10.3389/FIMMU.2021.626616
关键词:
摘要: Bispecific antibodies (BsAbs) are with two binding sites directed at different antigens or epitopes on the same antigen. The clinical therapeutic effects of BsAbs superior to those monoclonal (MoAbs), broad applications for tumor immunotherapy as well treatment other diseases. Recently, progress in antibody protein engineering and recombinant DNA technology, various platforms generating types based novel strategies, uses, have been established. More than 30 mature commercial technology used create develop heterologous recombination heavy chains matching light chains. detailed mechanisms clinical/therapeutic action demonstrated these BsAbs. Three kinds received market approval, more 110 stages trials. In this paper, we elaborate classic platforms, mechanisms, We hope that review can stimulate new ideas development improve current strategies.